MedPath

Tertiary Prevention by Exercise in Colorectal Cancer Therapy

Not Applicable
Completed
Conditions
Colorectal Cancer
Interventions
Behavioral: Physical activity
Registration Number
NCT01991847
Lead Sponsor
Technical University of Munich
Brief Summary

The purpose of this study is to determine the feasibility of a one year exercise training program in post-surgical patients with colorectal cancer.

Detailed Description

Apart from a genetic predisposition lifestyle factors (low physical activity, nutrition, and obesity) increase the risk of colorectal cancer. Furthermore, in observational studies increased physical activity has shown to improve the prognosis in patients after the diagnosis of colorectal cancer. However, there are currently no prospective randomized controlled trials which prove the causal relationship between exercise and prognosis in colorectal cancer patients. The long-term aim of this study is to evaluate whether physical activity of ≥ 18 MET-h (Metabolic equivalent task-hours) per week significantly improves disease free survival in colorectal cancer survivors (stage UICC II/III). In the first instance, structure-, process- as well as outcome-characteristics need to be investigated within a feasibility study (F-PROTECT). Essential aims are to establish collaborations with clinics and training centres, to achieve the required recruitment numbers, and to conduct the training intervention.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • histologically confirmed nonhereditary primary Stage II or III colon cancer diagnosis or rectal cancer
  • written informed consent in German
  • histopathologically confirmed R0-resection
  • start of guideline conformed adjuvant chemotherapy within 12 weeks after R0-resection in Stage III colon cancer diagnosis (if necessary in Stage III colon cancer diagnosis)
Exclusion Criteria
  • hereditary colon cancer diagnosis
  • R1 and R2 resection
  • clinically relevant complications during recovery
  • secondary neoplasm
  • non-continuance of guideline conformed therapy
  • uncontrolled infection
  • manifest cardiac disease (e.g. unstable CAD, heart failure (NYHA IV), malignant hypertension)
  • clinical relevant respiratory disease (GOLD IV)
  • musculoskeletal disorders severely restricting the patients mobility (e.g. gonarthrosis, coxarthrosis)
  • cirrhosis of the liver (Child B and C)
  • Karnofsky performance status scale ≤ 60%
  • maximal exercise capacity ≤ 50 watt
  • clinically relevant lab factors (leukocyte count ≤ 3000/μl, thrombocyte count ≤ 20.000/μl, hemoglobin < 8 g/dl)
  • physical activity level ≥ 18 MET-h/ week at screening

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Physical activityPhysical activityPhysical activity
Primary Outcome Measures
NameTimeMethod
Target sample sizeone year

The primary outcome measure is to successfully recruit 50 colorectal cancer patients, and to achieve 70% compliance to regular exercise over one year.

Secondary Outcome Measures
NameTimeMethod
Cancer related fatigueat screening and 6 and 12 month after baseline

Fatigue will be measured using the German version of the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-FA13; reduced version with 13 items).

Adverse and serious adverse eventsone year

Adverse (e.g. dizziness, high blood pressure) and serious adverse events (e.g. death, prolonged hospitalization) will be reported within 24 hours to the study physician via form.

Physical activityat screening and 3, 6, 9, and 12 month after baseline

Physical activity will be measured using physical activity diary, heart rate monitor (Sigma Sport PC 22.13), accelerometer (Aipermotion 440), and the German version of the International Physical Activity Questionnaire (IPAQ).

Peak oxygen consumptionat baseline and 12 month after baseline

Spiroergometry will be used to assess peak oxygen consumption (VO2peak).

Patient satisfactionat 3, 6, 9, and 12 month after baseline

Patient satisfaction will be measured using questionnaire.

Anxiety and depressionat screening and 6 and 12 month after baseline

Anxiety and depression will be assessed with the German version of the Hospital Anxiety and Depression Scale (HADS-D).

Cancer related quality of lifeat screening and 6 and 12 month after baseline

Cancer related quality of life will be assessed with the German Version of the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30).

Quality of life in colorectal cancerat screening and 6 and 12 month after baseline

Cancer related quality of life will be assessed with the German Version of the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire in colorectal cancer (EORTC QLQ-CR29).

Trial Locations

Locations (1)

Department of Medicine, Division of Prevention and Sports Medicine TU Munich

🇩🇪

Munich, Germany

© Copyright 2025. All Rights Reserved by MedPath